A quick, safe head-turn test (fHIT) can spot and measure balance and eye-movement problems in people with relapsing-remitting MS, and it gets worse when brain lesion load is higher.
Researchers tested 36 people with relapsing-remitting MS using a simple eye and head test called the functional head impulse test (fHIT). They split patients into those with vestibular symptoms (like vertigo, balance trouble, or eye jerking called nystagmus) and those without symptoms. People with vestibular symptoms did worse on the fHIT, meaning they correctly saw fewer visual targets during quick head turns. The worse the symptom score (more symptoms present), the worse the fHIT performance, showing the test matches how people feel. More MS brain lesions, especially near the brain’s ventricles (fluid spaces), were linked to poorer fHIT scores, suggesting brain damage relates to the balance and eye problems.
People with MS should care because this test can quickly show balance and vision-in-motion problems that might not be obvious during a routine visit. Caregivers can use the idea of a simple, fast check to decide if a doctor or therapist should be consulted sooner — like noticing wobbling when someone turns their head quickly. Neurologists and rehab therapists can use fHIT results to track changes over time and tailor therapy, similar to measuring blood pressure to guide medicine. Patients who have dizziness, unsteady walking, or eye movement complaints benefit most, because the test links these symptoms to measurable brain changes. Knowing this can help teams plan treatments or balance exercises earlier, possibly preventing falls or improving daily activities.
This study was small (36 people) and only looked at one type of MS (relapsing-remitting), so results might not apply to everyone with MS. The fHIT shows a link between symptoms, test results, and lesion count, but it does not prove the lesions cause the balance problems by themselves. More and longer studies are needed to confirm if the fHIT can reliably track worsening over time or predict who will benefit most from specific treatments.
AI-generated summary — for informational purposes only, not medical advice
12/31/2026
Learn how certain gut bacteria can worsen MS symptoms and what this means for treatment and daily li
Read More5/1/2026
Study finds a brain‑seeking CD4 killer cell tied to MS and CMV exposure that may resist some treatme
Read More5/1/2026
Study shows after optic neuritis the ganglion cell layer (GCL) loses more tissue than the inner plex
Read More5/1/2026
Study finds CD29 marks blood B cells that can enter the brain and become antibody-producing cells in
Read More5/1/2026
Study finds specific spinal fluid proteins tied to early nerve damage in active MS, highlighting imm
Read More5/1/2026
Study finds early detection, lower spinal fluid virus, and PML‑IRIS relate to better 1‑year outcomes
Read MoreWhether you’ve recently been diagnosed with Multiple Sclerosis (MS) or are seeking to broaden your understanding of this complex, neurodegenerative disease, navigating the latest research can feel overwhelming. Studies published in respected medical journals like Journal of neurology often range from early-stage, exploratory work to advanced clinical trials. These evidence-based findings help shape new disease-modifying therapies, guide symptom management techniques, and deepen our knowledge of MS progression.
However, not all research is created equal. Some clinical research studies may have smaller sample sizes, evolving methodologies, or limitations that warrant careful interpretation. For a more comprehensive, accurate understanding, we recommend reviewing the original source material—accessible via the More Details section above—and consulting with healthcare professionals who specialize in MS care.
By presenting a wide range of MS-focused studies—spanning cutting-edge treatments, emerging therapies, and established best practices—we aim to empower patients, caregivers, and clinicians to stay informed and make well-informed decisions when managing Multiple Sclerosis.